Dr Reddy's Confirms Gilead Licence Deal for Once-Yearly Lenacapavir for HIV Prevention Written By Parthika Patel18 Sept 2026 10:45 PM ISTHyderabad: Dr. Reddy's Laboratories Limited has confirmed that it has received a voluntary licence from Gilead Sciences for an investigational...
Gilead Wins USFDA Approval for Bixlenvo HIV Combination Treatment Written By sheeba farhat30 Aug 2026 3:13 PM ISTBengaluru: The U.S. Food and Drug Administration has approved Gilead Sciences' once-daily oral combination pill for treatment of adults whose HIV...
Dr Reddys, Emcure Lenacapavir Gets CDSCO Panel Nod for CT, BE Waivers in HIV PrEP Written By Susmita Roy25 Aug 2026 8:00 PM ISTNew Delhi: In a significant regulatory development that could expand access to long-acting HIV prevention in India, pharmaceutical majors Dr. Reddy's...
Weekly Oral Islatravir-Lenacapavir Noninferior to Daily HIV Therapy in Phase 3 Trial Written By Medha Baranwal30 July 2026 11:15 PM ISTGermany: A phase 3 international clinical trial has shown that a once-weekly oral combination of islatravir and lenacapavir is as effective as the...
US, Global Fund Scale Up Rollout of Lenacapavir Across 20+ Countries Written By sheeba farhat16 April 2026 8:02 PM ISTNew Delhi: The U.S. and the Global Fund to Fight AIDS, Tuberculosis and Malaria are ​stepping up efforts to broaden access to Gilead's HIV prevention...
South Africa Pushes for Local Manufacturing of Gilead's HIV Drug Lenacapavir to Boost Access Written By sheeba farhat6 March 2026 10:43 PM ISTLondon: South Africa is asking local drugmakers to start a process to make Gilead Sciences' long-acting HIV prevention drug, lenacapavir,...
Single daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens: Study Written By Dr. Kamal Kant Kohli2 March 2026 9:00 PM ISTA phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two...
Once-Weekly Oral Islatravir Plus Lenacapavir maintain high rates of virologic suppression in adults with HIV: Study Written By Dr. Kamal Kant Kohli24 Dec 2025 8:45 PM ISTA phase 2 randomized study evaluating the efficacy and safety of once-weekly oral islatravir plus lenacapavir (ISL+LEN) in virologically suppressed...
CDSCO Panel Rejects Hetero Lab's Plea for Lenacapavir Approval Without Local Trials Written By Parthika Patel9 Dec 2025 3:12 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has declined the proposal submitted by...
Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3 trial Written By Ruchika Sharma18 Nov 2025 12:30 PM ISTFoster City: Gilead Sciences has announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the...
Game-Changer for HIV: Dr Reddy's, Hetero to Sell Generic Lenacapavir at Rs 3,547 a Year Farhat Nasim25 Sept 2025 3:51 PM ISTBengaluru: Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions of a new and highly...
Gilead Sciences gets European Commission marketing authorization for twice yearly Yeytuo for HIV prevention Written By Ruchika Sharma27 Aug 2025 4:09 PM ISTFoster City: Gilead Sciences, Inc. has received the European Commission (EC) marketing authorization for Yeytuo (lenacapavir)-the company's...
